EATG » Highlights from the CHMP December meeting

Highlights from the CHMP December meeting

At its December meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for approval a generic version of efavirenz/emtricitabine/tenofovir disoproxil – Efavirenz/Emtricitabine/Tenofovir disoproxil Krka for the treatment of HIV infection.

Summary of opinion for Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is available here.

CHMP also recommended an extension of indications for Truvada (eemtricitabine/tenofovir disoproxil) with marketing authorisation holder Gilead Sciences International Limited.

Summary of opinion for Truvada is available here.

Share on FacebookTweet about this on TwitterShare on Google+Pin on PinterestShare on LinkedIn
Source:
EMA
News categories: HIV treatment, EMA/FDA